Cathie Wood的ARK ETF于2025年4月10日（星期四）出版了他们的日常交易

投入：Cathie Wood的ARK ETF于2025年4月10日（星期四）发布了日常交易，重点是基因组编辑和加密货币领域。当天最大的投资是Beam Therapeutics Inc（NASDAQ：BEAM），ARK的ARKK ETF收购了135,247股，价值约221万美元。这次购买强调了方舟对尖端CRISPR基因编辑技术的日益兴趣，因为Beam Therapeutics以其开创性的基础编辑技术而闻名，该技术允许进行精确和有针对性的遗传修饰。

Cathie Wood’s ARK ETF has been busy today, making several notable trades in the genomic editing and cryptocurrency sectors.

Cathie Wood的ARK ETF今天一直很忙，在基因组编辑和加密货币领域进行了几项著名的交易。

According to reports, ARK’s ARKK ETF engaged in some substantial buying activity. The ETF bought 135,247 shares of Beam Therapeutics (NASDAQ:BEAM) for approximately $2.21 million. This purchase continues a series of investments in Beam this week, showcasing ARK’s growing interest in the cutting-edge CRISPR gene editing technology. Beam Therapeutics is known for its pioneering base editing technology, which allows for precise and targeted genetic modifications.

据报道，ARK的ARKK ETF从事了一些大量的购买活动。 ETF以大约221万美元的价格购买了135,247股Beam Therapeutics（NASDAQ：BEAM）。这次购买持续了本周对Beam的一系列投资，展示了ARK对尖端CRISPR基因编辑技术的日益兴趣。 Beam Therapeutics以其开创性的基础编辑技术而闻名，该技术允许进行精确和有针对性的遗传修饰。

In the realm of digital currencies, ARK added 11,849 shares of Coinbase Global (NASDAQ:COIN) to its ARKK ETF, amounting to roughly $2.09 million. This move comes amidst a series of recent investments in Coinbase, indicating ARK’s bullish stance on the cryptocurrency exchange platform.

在数字货币领域，方舟在其ARKK ETF中增加了11,849股Coinbase Global（NASDAQ：COIN）的股票，总计约为209万美元。此举是在最近在Coinbase上进行一系列投资的过程中进行的，这表明ARK在加密货币交换平台上的看涨立场。

The trade report also highlighted a significant buy of 48,909 shares of Tempus AI (NASDAQ:TEM), a technology company focusing on artificial intelligence and precision medicine, with a total value of approximately $2.14 million. Additionally, ARK invested in 10X Genomics (NASDAQ:TXG), a company specializing in gene sequencing technology, purchasing 191,500 shares valued at around $1.66 million.

该贸易报告还强调了一家专注于人工智能和精密医学的技术公司Tempus AI（NASDAQ：TEM）的48,909股，总价值约为214万美元。此外，ARK投资了10倍基因组学（NASDAQ：TXG），这是一家专门从事基因测序技术的公司，购买了191,500股，价值约166万美元。

On the sell side, ARK’s ARKG ETF parted with 33,500 shares of Repare Therapeutics (NASDAQ:RPTX), a firm engaged in the discovery and development of precision oncology drugs, for a relatively minor sum of $31,155. This continues a trend from the previous week where ARK consistently reduced its holdings in Repare Therapeutics, signaling a strategic shift away from the company.

在卖方面，ARK的ARKG ETF与33,500股Repare Therapeutics（NASDAQ：RPTX）分开，这是一家从事Precision肿瘤学药物的发现和开发的公司，相对较小的次数为31,155美元。从上一周开始，这延续了一个趋势，即方舟不断减少其在重新疗法方面的持股，这表明战略转移了公司。

The daily trade activity reflects ARK’s ongoing strategy to capitalize on disruptive innovation and technology. Investors following ARK’s trades will note the consistent interest in companies like Beam Therapeutics and Coinbase, suggesting a strong belief in the potential of gene editing and cryptocurrency as transformative forces in the near future.

日常贸易活动反映了ARK的持续战略，以利用破坏性创新和技术。在ARK的交易之后，投资者将注意到对Beam Therapeutics和Coinbase等公司的持续兴趣，这表明对基因编辑和加密货币作为变革力量的潜力具有强烈的信念。